The INNA-051 formulation is designed to enhance the body’s natural immune response, targeting individuals aged 60 and over who are at increased risk for complications from respiratory viral infections.
The US agency has given the go-ahead to Cour Pharmaceuticals to evaluate the safety and efficacy of CNP-201, a drug intended to treat peanut allergies.
An Oxford University trial, a world first, is looking at whether inoculating volunteers with doses of different combinations of two currently approved COVID-19 vaccines is effective.
Sanofi Pasteur has entered into a license and supply agreement with
Eisai for the use of their novel adjuvant designed to boost the
immune response to a broad range of vaccines.
US company Sontra Medical has successfully completed the first
tests of a novel technology that allows vaccines to be applied
topically to the skin, rather than delivered through a needle.
Preliminary data suggest the method is as...
Researchers in the US have taken an important step toward creating
a vaccine against Alzheimer's disease, overcoming the side effects
that held back a prior vaccine for the disease.